A study revealed that the increased expression of Ly6K/E promotes cytokine-induced immune checkpoint molecules PDL1 and CTLA4 expression, enhances tumor-infiltrating T regulatory cells, and reduces natural killer cell activation. Here, LY6K is linked to neoplasm.